Literature DB >> 22153399

Modification of Plusoptix referral criteria to enhance sensitivity and specificity during pediatric vision screening.

Niraj R Nathan1, Sean P Donahue.   

Abstract

PURPOSE: To determine the impact of using several different proposed sets of referral criteria on the specificity and sensitivity of the plusoptiX S08 photoscreener for detecting amblyopia risk factors.
METHODS: During a 2-month period, 144 children ages 9 months to 14 years were screened at the Tennessee Lions Eye Center before receiving a comprehensive eye examination and cycloplegic refraction. Three previously published sets of referral criteria were used for screening, including the manufacturer's criteria and the criteria proposed by Arthur and colleagues, which are nearly identical to the gold standard examination failure thresholds proposed by the Vision Screening Committee of the American Association of Pediatric Ophthalmology and Strabismus (AAPOS). Modifications of these criteria also were evaluated. The screening results obtained by the plusoptiX S08 were compared with the results from the gold standard pediatric ophthalmologic examination, and the respective sensitivities and specificities of each set of referral criteria in detecting amblyopia risk factors identified by the AAPOS Vision Screening Committee were calculated.
RESULTS: The manufacturer's criteria yielded high sensitivity (100%) but very low specificity (37%). The Arthur criteria, which used the values for the AAPOS-defined amblyopia risk factors as referral criteria, maintained sensitivity (89%) and greatly improved specificity (76%). Two modifications of the Arthur criteria further increased specificity with minimal loss of sensitivity.
CONCLUSIONS: The manufacturer's criteria have excellent sensitivity but low specificity, warranting modification; other criteria increase specificity with minimal effect on sensitivity.
Copyright © 2011 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22153399     DOI: 10.1016/j.jaapos.2011.08.008

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  7 in total

1.  Photoscreeners in the pediatric eye office: compared testability and refractions on high-risk children.

Authors:  Mae Millicent W Peterseim; Carrie E Papa; M Edward Wilson; Edward W Cheeseman; Bethany J Wolf; Jennifer D Davidson; Rupal H Trivedi
Journal:  Am J Ophthalmol       Date:  2014-08-01       Impact factor: 5.258

2.  Beyond screening for risk factors: objective detection of strabismus and amblyopia.

Authors:  Reed M Jost; Susan E Yanni; Cynthia L Beauchamp; David R Stager; David Stager; Lori Dao; Eileen E Birch
Journal:  JAMA Ophthalmol       Date:  2014-07       Impact factor: 7.389

3.  A comparison of referral criteria used by the plusoptiX photoscreener.

Authors:  Eric Singman; Noelle Matta; Jing Tian; David Silbert
Journal:  Strabismus       Date:  2013-09

4.  Performance of the Plusoptix A09 photoscreener in detecting amblyopia risk factors in Chinese children attending an eye clinic.

Authors:  Xiao-Ran Yan; Wan-Zhen Jiao; Zhi-Wei Li; Wen-Wen Xu; Feng-Jiao Li; Li-Hua Wang
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

5.  Vision screening for children 36 to <72 months: recommended practices.

Authors:  Susan A Cotter; Lynn A Cyert; Joseph M Miller; Graham E Quinn
Journal:  Optom Vis Sci       Date:  2015-01       Impact factor: 1.973

6.  Evaluation of the PlusoptiX photoscreener in the examination of children with intellectual disabilities.

Authors:  Lina H Raffa; Abdulrahman Al-Shamrani; Ali AlQarni; Firas Madani; Kareem Allinjawi
Journal:  Saudi J Ophthalmol       Date:  2021-02-27

7.  Pediatric vision screening using the plusoptiX A12C photoscreener in Chinese preschool children aged 3 to 4 years.

Authors:  Dan Huang; Xuejuan Chen; Xiaohan Zhang; Yue Wang; Hui Zhu; Hui Ding; Jing Bai; Ji Chen; Zhujun Fu; Zijin Wang; Hu Liu
Journal:  Sci Rep       Date:  2017-05-17       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.